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Summary:  
This study collates all non-communicable disease (NCD) data in Kenya, combines it with a 
model to provide the first country-level NCD estimated by HIV-status. The results show a 
large and growing NCD burden, highlighting the need for NCD service expansion. 
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Abstract 
Background: The non-communicable disease (NCD) burden in Kenya is not well 
characterised, despite estimates needed to identify future health priorities. We aim to 
quantify current and future NCD burden in Kenya by HIV status.  
Methods: Original systematic reviews (SRs) and meta-analyses of prevalence/incidence of 
cardiovascular disease (CVD), chronic kidney disease, depression, diabetes, high total 
cholesterol, hypertension, human papillomavirus infection and related pre-cancerous stages 
in Kenya were carried out. An individual-based model was developed, simulating births, 
deaths, HIV-disease and treatment, aforementioned NCDs and cancers. The model was 
parameterised using SR, epidemiological national and regional surveillance data. NCD 
burden was quantified for 2018-2035 by HIV status amongst adults. 
Findings: SRs identified prevalence/incidence data for each NCD, except ischemic heart 
disease. The model estimates that 51% of Kenyan adults currently suffer from ≥1 NCD, with 
a higher burden in People Living with HIV (PLHIV) compared to HIV-negative (62% versus 
51%), driven by their higher age profile and partly by HIV-related risk for NCDs. 
Hypertension and high total cholesterol are the main NCD drivers (adult prevalence of 
20·5% (5·3 million) and 9·0% (2·3 million)), with CVD and cancers the main causes of death. 
The burden is projected to increase by 2035 (56% in HIV-negative; 71% in PLHIV), with 
population growth doubling the number of people needing services (15·4 million to 28·1 
million) by 2035.  
Conclusions: NCD services will need to be expanded in Kenya. Guidelines in Kenya 
already support provision of these amongst both the general and HIV-positive population, 
however coverage remains low.  
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Introduction 
In Kenya, the National AIDS Control Council and the Division of non-communicable 
diseases at the Ministry of Health have recently called for a paradigm shift focused on 
providing health services for NCDs within HIV-care platforms, for both People Living with 
HIV (PLHIV) and HIV-negative people [1,2], as a way of ensuring rapid scale up of services 
for NCDs. HIV care platforms provide an opportunistic entry-point for NCD services, 
especially now that HIV care includes NCDs and their complications [3]. They have a strong 
and large infrastructure within Kenya, mature partnerships, multisectoral networks and 
robust and resilient capabilities [3]. Evidence from observational studies [4] and 
mathematical modelling studies [5–7] in other countries has consistently shown that NCDs 
are more prevalent among PLHIV than HIV-negatives, a disproportionate burden that is 
expected to increase in the coming decades.  
 
Currently, the national-level burden of NCDs in Kenya is not well characterised, and there is 
no information on the prevalence by HIV-status. Such estimates and forecasts will be key to 
inform strategic planning on integration in the country. The aim of this study is to combine 
original systematic reviews (SR) and meta-analyses (MA) of available data on NCDs in 
Kenya, national and regional surveillance and demographic data and advanced modelling 
approaches to provide robust national-level estimates of the burden of NCDs in Kenya, by 
HIV status, currently and in the coming two decades.  
 
Methods 
Systematic reviews and meta-analyses 
Original SRs and MAs were carried out according to MOOSE and PRISMA guidelines [8–
10], summarising in-country evidence of overall and age-specific prevalence or incidence of 
NCDs including cardiovascular disease (CVD; specifically ischemic heart disease (IHD) and 
stroke), chronic kidney disease (CKD), depression, diabetes, high total cholesterol, 
hypertension, and human papillomavirus (HPV) infection and related cervical intraepithelial 
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neoplasia (Supplement 1). All NCDs were defined using standard Kenyan clinical definitions 
(Table 1). Briefly, Medline and Embase were searched from inception to May 2018 for 
population-based or primary care-based studies reporting on prevalence or incidence of 
these NCDs in Kenya. Due to the difficulty of diagnosing cancers at the community-level, 
cancer estimates were obtained from the Cancer Incidence in 5 Continents (version XI - 
IARC) for Kenya [11]. SRs were expanded to Tanzania, where data for Kenya was 
unavailable, assuming Tanzania to be comparable with regards to demography, burden of 
disease and healthcare profile. Two independent reviewers screened the search results in 
Mendeley, with disagreement resolved by a third reviewer. MAs were carried out on overall 
and age-specific prevalence/incidence estimates where more than one study was found. As 
the SR & MA included all available observational studies in the country, the risk of bias was 
assessed by adhering to specific recommendations from the MOOSE checklist. Specifically, 
this reporting guideline’s checklist specifies that included studies should have a qualitative 
assessment of bias in their discussion. Details of this assessment are further discussed in 
Supplement 1. Age-standardization prevalence or incidence (ASP or ASI) was calculated 
using standard direct method and World Health Organization standard population [12]. 
 
Model  
An individual-based multi-disease model coded in C++ was adapted for Kenya (Fig 1). The 
model design and mechanism has been described previously,[5] with technical details on the 
adaptation in Supplement 2. The model simulates the whole Kenyan population, tracking 
individual’s sex, age, births, deaths, HIV infection, disease progression and treatment and 
the development of several NCDs. These include those from the SR and a number of 
cancers (including: breast, cervical, colorectal, leukaemia, liver, oesophageal, stomach and 
prostate cancer and ‘other’ cancers where ‘other’ refers to all cancers except the 
aforementioned). Cervical cancer is simulated by including a natural history model of HPV 
infection and progression through pre-cancerous lesions (Fig 1) (Supplement 2). NCDs 
included those estimated to contribute the largest disease burden currently, and in the 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1103/5627699 by guest on 19 N
ovem
ber 2019
  5 
future, and for which sufficient data were available to make robust predictions, with choice of 
individual cancer based on those that contribute more than 50% of all non-AIDS defining 
cancer cases in Kenya as per 2018 IARC [11].  
 
Model adaptation drew on a number of data sources (Table 2). Parameters for demographic 
processes (birth and death rates) were from United Nations’ Department of Economic and 
Social Affairs for Kenya [13], and parameters on HIV epidemic (HIV incidence and ART 
coverage) were taken from the UNAIDS official estimates for Kenya [14]. These parameter 
sets changed over calendar time as reported by the data sources, for example decreasing 
mortality rate over time. Parameters for HIV disease progression are based on estimates 
from a modelling study for the Sub-Saharan Africa region [15]. 
 
Age-specific incident rates for each NCD and a fixed excess relative risk of death for each 
cause were inferred by fitting to data on incidence (for: stroke and cancers) from the SR and 
IARC (for cancers), prevalence (for the remaining NCDs) from the SR, and data on deaths 
by cause from the 2016 Global Burden of Disease (GBD) [16] based on pre-specified 
functional models for all persons. Hypertension and depression were assumed not to be an 
independent cause of death in the model, while the model assumes an additional 
instantaneous risk of death for stroke and IHD. Recurrent depression but only first CVD 
event are modelled. Of note, as no data was found on IHD in Kenya or Tanzania, the model 
assumed a four-fold increased incidence compared to stroke based on a large cross-
European study of CVD incidence [17].  
 
The model is run forward over time under further assumptions about how risk of NCD 
acquisition varies according to underlying conditions (Table 3). For example, an older 
individual or a person with pre-existing hypertension is more likely to develop a CVD 
compared to a younger individual without hypertension. These associations are based on in-
depth literature reviews (Fig 1 – red arrows; Table 3).  
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The model runs from 1950 to 2035, with the period from 1950 to 2015 used to carry out a 
number of model checks to ensure the model output is robust (supplement 2). The model is 
used to generates NCD estimates from 2018 to 2035 by HIV status. Projections assume 
medium variance demographic projections, HIV incidence to remain stable at 2017 levels, 
and that ART coverage increases steadily to reach a level of coverage consistent with 
90:90:90 targets. Patterns of underlying risk factors for NCD are assumed to remain 
unchanged, and treatment for NCDs was not explicitly simulated, instead the model implicitly 
assumes that current treatment coverage will remain constant over time. Sensitivity analyses 
was carried out to explore the impact of varying the age-specific incidence of individual 
NCDs by +/-10% (Supplement 2). All results are reported in adult populations (aged 18 
years and over) and based on an average of 100 model runs.  
 
Results  
Systematic Review and Meta-analysis 
A summary of the NCD estimates for Kenya collated by the SRs and MA is presented in 
Table 4. The SRs identified studies for most of the NCDs, except IHD. No Kenyan studies 
reporting on stroke incidence or age-specific prevalence of CKD were identified, with one 
was identified for each outcome when the SR was expanded to include Tanzania. The SRs 
found few studies reporting prevalence or incidence by HIV status, the notable exceptions 
being HPV and related cervical intraepithelial neoplasia and CKD.  
 
The largest number of studies (n=22) were found for hypertension, which also had the 
highest prevalence with the MA calculating a crude prevalence 25·6%, 95% CI 21·1-30·1) 
and ASP of 28·7% (23·6 to 33·8). High total cholesterol, CKD and depression were also 
prevalent (crude prevalence 11·7% (95% CI 11·3 to 12·0); 10·1% (95% CI 6·2 to 14·0) and 
9·0% (95% CI 8·1 to 9·9%), and ASP of; 12·1% (95% CI 7·2 to 17·0), 9·2% (95% CI 4·6 to 
13·8) and 6·4% (95% CI 4·3 to 8·5, respectively).  
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Current demographic and epidemiological estimates 
The model estimates that out of 49·6 million Kenyans, 1·6 million are PLHIV. Mean age in 
the general population is estimated to be 22 years old, compared to 33 years old amongst 
PLHIV.  
 
According to the model, an estimated 51% of Kenyan adults currently suffer from ≥1 NCDs 
(i.e. hypertension, high total cholesterol, diabetes, depression, CVD, CKD and/or cancer). 
The burden is estimated to be higher amongst adult PLHIV compared to HIV-negative adults 
(62% in PLHIV versus 51% in HIV-negative). This  is mainly driven by the older age of 
PLHIV and to a lesser extent by HIV-related risk for NCDs (ASP of diabetes is 1·0% in 
PLHIV and 1·1% in HIV-negative, for which HIV is not assumed to be a risk factor versus 
ASP of hypertension is 34·6% in PLHIV and 28·0% in HIV-negative, for which HIV is 
assumed to be a risk factor).  
 
Hypertension and high total cholesterol are the main cause of NCD burden, with an adult 
prevalence of 20·5% (5·3 million people) and 9·0% (2·3 million people), respectively. Other 
CVD-related NCDs are also estimated to be high (CKD 5·6% (1·4million people) and 
diabetes 2·7% (0·7 million)). CVD and cancers are the main causes of death in Kenya in 
2018 (Fig 1D).  
 
Future demographic and epidemiological estimates 
The model estimates that the total population of Kenya will increase from 49·6 million in 
2018 to 76·7 in 2035. Assuming HIV incidence rates remain unchanged and ART coverage 
increases steadily to reach the 90:90:90 goals by 2020, the population of PLHIV will 
increase from 1·6 to 2·7 million people. Mean age is predicted to increase from 22 in 2018 to 
24 in the general population and from 33 to 40 amongst PLHIV between 2018 and 2035.  
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The NCD burden is forecasted to increase in the coming decades but remain consistently 
higher among PLHIV; by 2035, 56% of HIV-negative Kenyan adults and 71% of adult PLHIV 
will suffer from ≥1 NCD. The model predicts that the NCD burden would remain substantial, 
even if pooled estimates overestimated individual NCD burden, (10% reduction in age-
specific NCD incidence would translate to 55% of HIV-negative and 69% of PLHIV with ≥1 
NCD in 2035). While the demographic shift will result in an increased NCD burden over time 
(irrespective of HIV status), population growth will result in a sharp increase in the absolute 
number of adults needing services for NCD. The prevalence of hypertension, for example, is 
expected to rise from 20% to 24% between 2018 and 2035, assuming current coverage of 
prevention and treatment services remain unchanged. However, the number of adults with 
hypertension is expected to increase from 5·3 million to 10·3 million, with 7·2 million new 
cases in this time period. As a result, the number of adult PLHIV and HIV-negative people 
needing services for NCD will increase from 1·1 million and 14·3 in 2018 to 2·2 million and 
25·9 million by 2035, respectively (Fig 2A).  
 
The number of adults living with high total cholesterol, diabetes and CKD are also expected 
to increase in this time period (Fig 2B), with 3·0 million, 1·1 million and 2·1 million new cases 
predicted between 2018 and 2035. As a result of these increases in CVD-related NCDs, 
CVD incidence is predicted to increase between 2018 to 2035. The model predicts that 
32,000 adult PLHIV and 444,100 of HIV-negative adults will experience a first CVD event in 
this period (Fig 2C), with a higher age-standardized incidence (ASI) amongst PLHIV (822·7 
per 100,000 in 2020-2025 versus 814·9 per 100,000 in 2030-2035) than HIV-negative 
adults(754·2 per 100,000 in 2020-2025 versus 759·7 per 100,000).  
 
Depression is also an important contributor to NCD burden, with 16·4 million new cases of 
depression expected between 2018 and 2035 (Fig 2C). The prevalence of depression in 
2018 is expected to remain stable at 3·4%, with a higher burden in adult PLHIV compared to 
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HIV-negative adults (3·9% versus 3·3%). This is mainly due to the increased risk for 
depression amongst PLHIV.  
 
With regards to cancers, the model estimates that crude incidence of cancers as a whole in 
the total population will increase steadily from 309·76 per 100,000 in PLHIV and 47·71 per 
1000,000 in HIV-negative adults in 2018 to 343·23 per 100,000 and 55·42 per 100,000 in 
2035, respectively. The model estimates that a cumulative 0·55 million adults in Kenya will 
be diagnosed with any cancer between 2018 and 2035. Of those, 20·0% will be caused by 
cervical cancer, 18·0% by breast cancer, 11·6% by prostate and 10·2% by oesophageal 
cancer, 7·7% by colorectal cancer, 4·7% by stomach cancer, 3·7% by leukaemia, 2·6% by 
liver cancer and 21·2% by other cancers. Table S2.4 to S2.7 in Supplement 2 provide more 
detailed estimates of NCDs by HIV status and age from 2020 to 2035.  
 
Discussion 
Assuming current coverage of preventative and curative NCD service, the burden of NCDs 
in Kenya is set to increase in the coming 20 years, particularly in PLHIV. The increase in 
NCD burden will be driven by population growth, and amongst PLHIV largely by the rapidly 
ageing and, to a lesser extent, the cumulative exposure to HIV and ART. While NCD 
prevalence is predicted remain relatively stable, demographic growth will result in twice the 
number of adults needing services for NCDs in Kenya by 2035.  
 
Although clear guidelines are already in place [1,18], service coverage remains low. The 
high and accelerating burden of NCDs will put further pressure on the health system 
planning with failure to act undermining both public health and ART programmes in the 
country. Time-updated estimates and projections such as those generated here, will be 
important in supporting these efforts. Routine collection of in-country NCD program data will 
be vital to support these efforts.  
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Policy makers in Kenya are calling for the integration of services for NCD into HIV platforms 
as a way to facilitate rapid scale up of NCD services. HIV care has evolved into a chronic 
care model and has been successfully integrated with other services (e.g. services for 
nutrition, tuberculosis and maternal health) and could be leveraged to providing services for 
NCDs. However, questions remain on how to best operationalise integration and how these 
platforms, set up to deal with a low prevalent disease such as HIV, could handle more 
prevalent conditions such as hypertension without decreasing the quality of care. For 
integration to work, it will need to be underpinned by context-specific evidence. Research 
needs to explore the aforementioned questions and explore operationalisation of integration, 
identify cost-effective delivery models, and identify effective prevention campaigns. Spare 
capacity in HIV facilities, particularly given the move to differentiated care of stable, 
virologically supressed PLHIV needs to be monitored [19] and pilot studies are needed, 
demonstrating whether integration of NCD services into HIV platforms is cost-saving.  
 
Our findings amongst PLHIV are similar to those reported in other settings. Modelling 
studies from Botswana, Italy, The Netherlands, the USA and Zimbabwe all forecast a rapid 
ageing of PLHIV paralleled by a growing burden of NCDs [5,7,20,21]. In Italy and the USA 
and estimated 89% of PLHIV will suffer from ≥1 NCD in 2035, compared to 59% in 
Zimbabwe and 62% in Kenya in 2035 [5,7]. Despite a large overlap in the NCDs included in 
each of these study (hypertension, diabetes, CVD, CKD, cancers), they each include a 
different number and type of NCDs, making it hard to make direct comparison. 
 
This is the first study to combine all country-specific data on NCDs in a low-middle income 
HIV endemic setting into a modelling framework and provide detailed country-level NCD 
estimates by HIV status, currently and in the coming decades. Similar studies have been 
limited by the lack of available robust in-country estimated of NCDs. By using an individual-
based modelling approach this study is able to account for key risk factors for NCDs, 
including age, pre-existing conditions and infection with HIV.  
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A limitation arises from the NCD data availability in Kenya. Although the SR identified a 
wealth of data, the model still relies on data from neighbouring Tanzania, and data from 
high-income setting. For example, there is a lack of data on the prevalence of risk factors for 
NCDs and prevalence of NCDs by HIV status in Kenya, with the model relying on data from 
high-income settings. Consequently, we were not able to check the model output on NCD 
burden by HIV status to Kenyan data; with the exception of prevalence of HPV and CIN2/3, 
which were compared to pooled estimates collated by the SR (Supplement 2). The 
contribution of HIV to NCD development is a topic of ongoing research and this study 
incorporated data consistent with our best understanding of this field. More research is 
needed to understand if the contribution of HIV-infection to the development of NCDs is 
consistent across settings. As new data becomes available, the model results can be 
updated. 
 
In addition, the model also has to make simplified assumptions around survival rates. The 
model fits to GBD estimates, in the absence of better cause-specific mortality estimates from 
Kenya. The model also does not account for contribution of risk factors such as smoking, 
alcohol or diet to the development of NCDs. Several studies have shown that PLHIV may be 
at an increased risk of smoking and drinking alcohol [4] and it is widely agreed that these 
factors increase the risk for a number of NCDs. However, there is a lack of consensus on 
the relative contribution of lifestyle factors to NCD risk and how this may differ by HIV status, 
and consensus on how these may change in the coming 20 years in Kenya. As a result, 
while the model account for overall lifestyle risk for NCDs, it assumes that the effect of 
lifestyle factors is uniform across the population and constant over time. If lifestyle factors 
such as smoking and alcohol are restricted to a small proportion of the population in Kenya, 
the model results may be overestimating the number of people suffering from one or more 
NCD.  
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Similarly, the model does not account for potential changes in health care access (other than 
90:90:90 scale-up) or structural changes which may impact both NCD and HIV burden, e.g. 
national prevention campaigns and how these may reduce NCD burden. The data on NCD 
burden in Kenya, obtained through the SR, only provides data on diagnosed cases of NCDs. 
While the review focused on population-based studies, this and the fact that the model does 
not simulate all NCDs, will result in the model underestimating the true burden of NCDs in 
Kenya. Finally, the model does not simulate communicable diseases and how these could 
impact the risk of NCDs (e.g. infection with hepatitis and liver cancer).  
 
In conclusion, Kenya is set to face growing NCD health care needs in the country. A rapidly 
growing population and continued HIV epidemic is expected to result in a growing NCD 
burden in the coming two decades, with the number of people needing services predicated 
to almost double. While guidelines in Kenya already support provision of NCD services 
coverage remains low. As policy aims to use integration of NCD services in HIV platform in 
Kenya to increase coverage of NCD services, more research will be needed to guide optimal 
approaches and planning.  
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Fig 1. Schematic of the multi-disease model for Kenya. The model simulates demography 
(blue), HIV epidemic (orange), and non-communicable diseases (green), and accounts for 
key interactions between demographic and disease-specific factors (red arrows to individual 
conditions and group of conditions).  
*Cervical cancer risk is higher in HIV-positive women, driven by the increased risk of HPV 
infection   
Abbreviations: Human Immunodeficiency Virus (HIV); antiretroviral therapy (ART); 
cardiovascular disease (CVD); human papillomavirus (HPV); cervical intraepithelial 
neoplasia (CIN); carcinoma in situ (CIS). 
 
Fig 2. Estimates and projections of NCD burden by HIV status in Kenya. A. Number of 
people in 2018 and 2035 by age group and HIV status; B. Numbers living with NCDs in 2018 
and 2035; C. Number of new cases between 2018 and 2035; D. Number of people dying of 
an NCD between 2018 and 2035.  
Notes: Depression is defined as having depressive episode in the past 12 months. CVD 
includes ischemic heart disease and ischemic stroke. Estimates of precancerous lesions of 
the cervix (CIN2+) are limited to women aged 15 and older.  
Abbreviations: cardiovascular disease (CVD); cervical intraepithelial neoplasia (CIN).  
 
Table 1. Clinical definitions of NCDs used for the systematic review.  
 
Table 2. Summary of model data sources  
 
Table 3. Model parameters defining relative risk of developing individual NCDs given pre-
existing NCD or HIV infection.  
Abbreviations: human immunodeficiency virus (HIV); human papillomavirus (HPV); 
antiretroviral therapy (ART); cervical intraepithelial neoplasia (CIN); carcinoma in situ (CIS). 
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*referring to all non-AIDS defining cancers other than the aforementioned, and cervical 
cancer.  
 
Table 4. Summary of NCD prevalence and incidence data for Kenya, as collated through 
systematic reviews and meta-analyses.  
Study period year is based on year of the relevant study, where more than one study was 
combined in a meta-analysis mean calendar year was calculated from included studies.  
Abbreviations: human immunodeficiency virus (HIV); human papillomavirus (HPV); 
antiretroviral therapy (ART); cervical intraepithelial neoplasia (CIN); carcinoma in situ (CIS). 
† defined as having had an episode in the past 12months. 
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Figure 1 
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Figure 2 
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Table 1 
NCD Definition 
Cardiovascular 
disease 
study-ascertained diagnosis (e.g. based on medical records or standardised 
acute diagnostic criteria) of ischaemic heart disease or ischaemic stroke; 
Chronic Kidney 
Disease 
an estimated glomerular filtration rate 60ml/min/1.73m2 body surface 
without evidence for acute kidney failure; 
Depression study-ascertained diagnosis based on medical records or standardised 
questionnaire (e.g. PHQ-9, CIS-R); 
Diabetes, type 2 fasting plasma glucose ≥7.0mmol/l (126mg/dl) or 2–h plasma glucose 
≥11.1mmol/l (200mg/dl); 
High total 
cholesterol 
≥5.19mmol/l (200mg/dl); 
Hypertension either the presence of pre-hypertension, at ≥130/80 and <140/90, or overt 
hypertension, at ≥140/90; 
HPV Study-ascertained diagnosis of HPV infection based on DNA detection 
methods in cervical swap or biopsy samples 
CIN lesions Study- ascertained diagnosis of CIN 2+ (i.e. CIN 2 to CIS) based on expert-
assessed cytology and/or biopsy 
Source: Ministry of Public Health and Sanitation.3 
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Table 2 
Parameter  Source 
Demographic processes  
Age composition in 1950 
Age-specific fertility rates from 1950 to 
2018 (by 5-year periods) 
Age-and-sex-specific death rates from 1950 
to 2018 (by 5-year periods) 
 
United Nations World Population Prospect 
HIV epidemic  
Annual age-and-sex-specific HIV incidence 
from 1975 to 2016 
Number of people starting ART by CD4 
count between 2000 and 2016 
 
UNAIDS estimates for Kenya  
HIV disease progression 
CD4 distribution at seroconversion by age 
and sex 
CD4 count progression rate by sex 
Age-and-sex-specific mortality rate by CD4 
count (ART-naïve) 
 
Mangel et al, AIDS (2017) estimates for SSA 
Cause-specific mortality 
*Risk ratio for HIV, CKD, diabetes, IHD, 
stroke, breast, cervical, colorectal, 
leukaemia, liver, oesophageal, stomach and 
prostate cancer and ‘other**’ cancers 
Case-fatality of stroke and IHD* 
Global Burden of Disease 2016 estimates 
for Kenya 
NCD epidemic 
*Age-specific NCD incidence of CKD, 
depression, diabetes, high total cholesterol, 
hypertension, stroke, breast, cervical, 
colorectal, leukaemia, liver, oesophageal, 
stomach and prostate cancer and ‘other**’ 
cancers* 
Relative risk of IHD versus stroke incidence 
Duration of depressive episode*** 
Probability of cervical disease progression, 
clearance§ 
Rate of progression through cervical 
disease§ 
Risk ratio of cervical disease progression for 
HIV-positive 
IARC 2012 cancer estimates for Kenya; 
systematic review and meta-analysis for 
NCDs other than cancer; European CVD 
Statistics 2017 for myocardial infraction: 
ischemic heart disease hazard ratio 
*these parameters were inferred by fitting to the data.  
**‘other’ refers to all cancers except the aforementioned 
***model assumption 
§stage-specific parameters were fitted, where no data was available 
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Table 3 
 
Abbreviations: human immunodeficiency virus (HIV); human papillomavirus (HPV); 
antiretroviral therapy (ART); cervical intraepithelial neoplasia (CIN); carcinoma in situ (CIS). 
*referring to all non-AIDS defining cancers other than the aforementioned, and cervical 
cancer. 
Association Hazard ration 
(95% CI) 
Reference: setting 
Non-HIV-related 
Incidence of stroke given pre-existing 
diabetes vs stroke with no pre-
existing diabetes 
2·431 (1·483–
2·492) 
Worm et al. [18]: 
Europe, Argentina, 
Australia, USA 
Incidence of stroke given pre-existing 
hypertension vs stroke with no pre-
existing hypertension 
1·426 (0·498–
1·462) 
Worm et al. [18]: 
Europe, Argentina, 
Australia, USA The 
Netherlands 
Onset of hypertension given pre-
existing diabetes vs hypertension with 
no pre-existing diabetes 
1·440 (1·419–
1·464) 
Smit et al. [10]: The 
Netherlands 
Chronic kidney disease given pre-
existing diabetes vs chronic kidney 
disease with no pre-existing diabetes 
1·450 (1·405–
2·415) 
Mocroft et al. [19]: 
Europe, Argentina, 
and Israel 
 
Chronic kidney disease given pre-
existing hypertension vs chronic 
1·469 (1·426–
2·427) 
Mocroft et al. [19]: 
Europe, Argentina, 
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kidney disease with no pre-existing 
diabetes 
and Israel 
HIV-related 
Hypertension given HIV infection vs 
hypertension without HIV infection 
1·449 Schouten et al. [20]: 
The Netherlands 
Chronic kidney disease given HIV 
infection vs chronic kidney disease 
without HIV infection 
2·04 Schouten et al. [20]: 
The Netherlands 
Depression given HIV infection vs 
depression without HIV infection 
3·1 Do et al. [21]: USA 
HPV infection given HIV infection and 
being ART-naïve or on ART for <2 
years vs HPV infection without HIV 
infection or with HIV infection and on 
ART for 2+ years 
1·63 (1·26-2·11) Looker et al. [22]: 
global systematic 
review and meta-
analysis 
Clearance of HPV infection given HIV 
infection and being ART-naïve or on 
ART <2 years vs clearance of HPV 
infection without HIV or with HIV 
infection and on ART for 2+ years 
0·52 (0·62-0·84) Looker et al. [22]: 
global systematic 
review and meta-
analysis 
Risk of transitioning from HPV to 
CIN2/3 with HIV infection and being 
ART-naïve or on ART <2 years vs 
risk of transitioning from HPV to 
CIN2/3 without HIV or with HIV 
1·32 (1·10-1·58) Liu et al. [23]: global 
systematic review and 
meta-analysis 
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infection and on ART for 2+ years 
Cancer (type-specific, excluding 
cervical cancer) given HIV infection 
vs. cancer without HIV infection: 
- Breast 
- Colorectal 
- Leukaemia 
- Liver 
- Oesophageal 
- Prostate 
- Stomach  
- Other cancers* 
 
 
0·7 
0·6 
1·2 
3·2 
1·2 
0·5 
0·7 
1·2 
Hernández-Ramírez 
et al. [24]: registry-
linkage study from 
USA cohorts of 
PLHIV, compared to 
the general 
population, from 1996 
to 2012 
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Table 4 
Abbreviations: human immunodeficiency virus (HIV); human papillomavirus (HPV); 
antiretroviral therapy (ART); cervical intraepithelial neoplasia (CIN); carcinoma in situ (CIS). 
† defined as having had an episode in the past 12months. 
Disease Age-
specific 
prevalence 
(95% CI) 
Crude 
prevalence 
(95% CI) 
Age-
standardised 
prevalence 
(95% CI) 
Country/Source Study 
Period 
Reference 
Chronic 
kidney 
disease* 
- 18 to 29 
- 30 to 39 
- 40 to 49 
- 50 to 59 
60 
 
 
5·9% (0·7 to 
11·2) 
6·2% (3·5 to 
8·9) 
10·4% (6·5 
to 14·3) 
12·4% (8·1 
to 16·6) 
14·4% (7·6 
to 21·3) 
 
 
10·1% (6·2 
to 14·0) 
 
 
9·2% (4·6 to 
13·8) 
 
 
Kenya and 
Tanzania, pooled 
using meta-
analysis 
 
 
2014 
 
 
[25–27] 
 
 
Depression*† 
- 18 to 29 
- 30 to 44 
- 45 to 59 
- 60 to 69 
70-79 
80 
 
3·2% (2·5 to 
3·9) 
9·0% (7·3 to 
10·7) 
4·9% (3·1 to 
6·7) 
7·4% (3·3 to 
11·5) 
12·8% (5·4 
to 20·2) 
4·4 (0 to 
12·8) 
 
8·5% (5·1 to 
11·8) 
 
6·3% (4·3 to 
8·5) 
 
Kenya 
 
2003 
 
[28–35] 
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Type 2 
diabetes* 
- 18 to 29 
- 30 to 39 
- 40 to 49 
- 50 to 59 
60 
 
1·6% (0·0 to 
3·3) 
2·7% (1·8 to 
3·5) 
4·6% (3·0 to 
6·2) 
5·8% (4·8 to 
6·8) 
7·6% (4·1 to 
11·2) 
 
5·2% (3·0 to 
7·3) 
 
4·0% (2·3 to 
5·7) 
 
Kenya, pooled 
using meta-
analysis 
 
2015 
 
[36–40] 
 
High total 
cholesterol* 
- 18 to 29 
- 30 to 39 
- 40 to 49 
- 50 to 59 
60 
 
 
8·5% (2·3 to 
14·7) 
11·6% (9·7 
to 13·4) 
10·5% (4·0 
to 17·1) 
14·6% (8·9 
to 20·4) 
18·1% (14·0 
to 22·2) 
 
 
11·7% (11·3 
to 12·0) 
 
 
12·1% (7·2 to 
17·0) 
 
 
Kenya, pooled 
using meta-
analysis 
 
 
2015 
 
 
[39,41,42] 
 
Hypertension* 
- 18 to 29 
- 30 to 39 
- 40 to 49 
- 50 to 59 
60 
 
13·8% (9·6 
to 18·1) 
18·9% (13·9 
to 24·0) 
29·6% (23·4 
to 35·9) 
42·6% (36·8 
to 48·4) 
52·5% (47·6 
 
25·6% (21·1 
to 30·1) 
 
28·7% (23·6 to 
33·8) 
 
Kenya, pooled 
using meta-
analysis 
 
2015 
 
[39,41–64] 
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to 57·4) 
Cervical HPV 
infection in the 
overall 
population* 
15-24 
25-29 
30-34 
35-39 
40 
 
 
 
31·9% (20·8 
to 43·0) 
32·9% (18·7 
to 47·2) 
29·1% (16·8 
to 41·5) 
33·8% (14·0 
to 53·5) 
28·0% (14·1 
to 41·9) 
 
 
 
36·5% (23·7 
to 49·3) 
 
 
 
30·1% (16·4 to 
43·8) 
 
 
 
Kenya 
 
 
 
2001 
 
 
 
[65–69] 
Cervical HPV 
infection in the 
HIV+ 
population* 
15-24 
25-29 
30-34 
35-39 
40 
 
 
 
69·6% (42·8 
to 96·5) 
64·3% (44·5 
to 84·1) 
58·2% (28·5 
to 87·8) 
60·0% (39·3 
to 80·8) 
56·0% (34·8 
to 77·3) 
 
 
 
54·7% (38·2 
to 71·3) 
 
 
 
60·6% (37·5 to 
83·8) 
 
 
 
Kenya 
 
 
 
2006 
 
 
 
[67,69–73] 
CIN 2/3 lesions 
in the overall 
population* 
15-24 
25-29 
30-34 
 
 
 
4·0% (0·1 to 
7·8) 
7·5% (4·1 to 
 
 
 
5·7% (3·5 to 
8·0) 
 
 
 
6·3% (2·7 to 
9·8) 
 
 
 
Kenya 
 
 
 
1997 
 
 
 
[65–69] 
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35-39 
40 
10·8) 
9·2% (5·2 to 
13·3) 
10·4% (5·1 
to 15·7) 
5·7% (2·6 to 
8·8) 
CIN 2/3 lesions 
in the HIV+ 
population* 
15-24 
25-29 
30-34 
35-39 
40 
 
 
3·3% (0·7 to 
5·8) 
13·3% (10·0 
to 15·0) 
8·4% (6·3 to 
9·4) 
8·6% (6·7 to 
9·4) 
8·2% (3·7 to 
10·0) 
 
 
13·4% (7·3 
to 19·5) 
 
 
7·7% (4·3 to 
9·5) 
 
 
Kenya 
 
 
2013 
 
 
[67,69–74] 
 
 Age-
specific 
incidence 
(95% CI) 
Crude 
incidence 
(95% CI) 
Age-
standardised 
incidence 
(95% CI) 
   
Stroke 
18 to 44 
45 to 54 
55 to 64 
65 to 74 
75 to 84 
>=85 
 
9·3 (4·7 to 
16·6) 
91·1 (74·4 to 
109·7) 
220·5 (193·8 
to 249·3) 
629·1 (584·0 
to 677·5) 
1432·6 
 
83·9 (67·7 to 
101·9) 
 
114·8 (102·7 
to 129·4) 
 
Tanzania 
 
2003-
2006 
 
[75] 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1103/5627699 by guest on 19 N
ovem
ber 2019
  31 
(1361·7 to 
1506·1) 
1933·7 
(1850·2 to 
2019·9) 
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